South Korean Firms to Inject 10 Trillion Won into Biotechnology by 2023
South Korean biotech companies, including Celltrion and Samsung Biologics, would jointly invest a total of 10 trillion won ($9.03 billion) ...
South Korean biotech companies, including Celltrion and Samsung Biologics, would jointly invest a total of 10 trillion won ($9.03 billion) ...
Celltrion Group announced on Tuesday that it plans to broaden its diagnostic portfolio for SARS-CoV-2 by introducing antigen and antibody ...
Celltrion Healthcare announced on Wednesday that it would commence clinical trials of Remsima, an anti-inflammatory biosimilar, on COVID-19 patients this month ...
Celltrion announced on Monday that its antiviral treatment candidate CT-P59 for COVID-19 positively lowered the amount of SARS-CoV-2 virus in ...
Celltrion said on Thursday that the company started to select through screening the most effective antibodies to neutralize the virus. ...
Celltrion, South Korea’s leading biosimilar developer, said it doubled its efforts to create a super-fast test kit designed to identify ...
Celltrion announced on Tuesday that the company would establish its first plant in Wuhan, China, stating that the facility would ...
Copyright © 2024 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |